Description
Your doctor may prescribe Ngenla, a human growth hormone (HGH) analog, for treating growth failure in pediatric patients three and older. Ngenla is used in patients with low secretion of endogenous growth hormone.
Ngenla works by mimicking the natural HGH hormone, binding to the growth hormone (GH) receptor, and initiating a signal cascade that stimulates increased growth and metabolism.
Directions
Ngenla's dosage is adjustable based on individual dosing requirements. The recommended frequency is once weekly, with an initial dosage of 0.66 mg/kg.
Ongoing dosage adjustments are made in response to observed growth.
To prevent abnormal fat tissue growth, injection sites should be rotated regularly.
Administered through prefilled pens containing 24 mg or 60 mg.
Ingredients
The active ingredient in Ngenla is somatrogron.
Interactions
Common drug-drug interactions with Ngenla may include:
- Acarbose
- Albiglutide
- Alclometasone
- Alogliptin
- Amcinonide
- Beclomethasone
- Betamethasone
- Budesonide
- Canagliflozin
- Chlorotrianisene
- Chlorpropamide
- Ciclesonide
- Clobetasol
- Clobetasone
- Clocortolone
- Cortisone
- Dapagliflozin
- Deflazacort
- Desonide
- Desoximetasone
- Dexamethasone
- Diethylstilbestrol
- Diflorasone
- Diflucortolone
- Difluprednate
- Dulaglutide
- Empagliflozin
- Ertugliflozin
- Esterified Estrogens
- Estradiol
- Estramustine
- Estropipate
- Ethinyl Estradiol
- Exenatide
- Flucloronide
- Flumethasone
- Flunisolide
- Fluocinolone
- Fluocinonide
- Fluocortin
- Fluocortolone
- Fluorometholone
- Flurandrenolide
- Fluticasone
- Glimepiride
- Glipizide
- Glyburide
- Halcinonide
- Halobetasol
- Hydrocortisone
- Insulin
- Insulin Aspart, Recombinant
- Insulin Bovine
- Insulin Degludec
- Insulin Detemir
- Insulin Glulisine
- Insulin Lispro, Recombinant
- Linagliptin
- Liraglutide
- Lixisenatide
- Loteprednol
- Medrysone
- Mestranol
- Metformin
- Methylprednisolone
- Miglitol
- Mometasone
- Nateglinide
- Paramethasone
- Pioglitazone
- Pramlintide
- Prednicarbate
- Prednisolone
- Prednisone
- Quinestrol
- Repaglinide
- Rimexolone
- Rosiglitazone
- Saxagliptin
- Semaglutide
- Sitagliptin
- Tibolone
- Tolazamide
- Tolbutamide
- Triamcinolone
- Voglibose
Cautions
Caution is advised for individuals with a history of cancer, diabetes, pancreatitis, thyroid disease, or other adrenal problems.
Regular assessment of intracranial hypertension during treatment is essential.
Ngenla may lead to fluid retention, requiring frequent monitoring.
Side Effects
Common adverse reactions may include:
- Anemia
- Angioedema
- Body fluid retention
- Cancer
- Cough
- Diabetes mellitus
- Fever
- Headache
- Hypoadrenalism
- Hypersensitivity reaction
- Hypothyroidism
- Impaired glucose tolerance
- Injection site disorder
- Intracranial tumor
- Nasopharyngitis
- Pancreatitis
- Progression
- Pseudotumor cerebri
- Scoliosis deformity of spine
- Slipped upper femoral epiphysis
- Vomiting
References
Ngenla [package insert]. New York, NY: Pfizer; June 2023.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14429